BACKGROUND: Following 7-valent conjugate vaccine introduction in the United States in 2000, invasive serotype (sero19A) pneumococcal disease (IPD) emerged rapidly. Sero19A IPD incidence increased slightly during 2005-2008 (from 2.3 cases to 2.5 cases per 100,000 population), whereas sero19A penicillin resistance (defined as a minimum inhibitor concentration [MIC] ≥2 μg/mL) increased significantly (from 28.7% to 43.7%). To better understand changes, we characterized sero19A isolates recovered during 2004-2008. METHODS: We performed antimicrobial susceptibility testing on all 2767 sero19A IPD isolates identified through the Centers for Disease Control Active Bacterial Core surveillance during 2004-2008. We genotyped 1804 (96.3%) of 1874 sero19A isolates recovered during 2005-2007 and all 148 year 2008 sero19A isolates from children <5 years of age. RESULTS: Resistant clonal complex (CC) 320/271(19A) increased from 20.9% (115 of 550) to 32.9% (208 of 633; P < .001) of IPD isolates during 2005-2007, which paralleled increased sero19A penicillin resistance (from 28.7% [163 of 567 isolates] to 39.5% [261 of 661 isolates]; P < .001). Total IPD due to 320/271(19A) increased during 2005-2007 and increased from 2.1 to 3.6 cases per 100,000 population during 2005-2008 in children <5 years of age. The penicillin-susceptible/intermediate, putative vaccine-escape CC695(19A) increased from 7.5% (41 of 550) to 13.6% (85 of 633) of sero19A isolates during 2005-2007 (P = .002). CONCLUSIONS: Sero19A rates may have plateaued; however, clonal shifts are increasing resistance. Increased IPD caused by CC320/271(19A) and CC695(19A) could reflect additional selective advantages in addition to resistance.
BACKGROUND: Following 7-valent conjugate vaccine introduction in the United States in 2000, invasive serotype (sero19A) pneumococcal disease (IPD) emerged rapidly. Sero19A IPD incidence increased slightly during 2005-2008 (from 2.3 cases to 2.5 cases per 100,000 population), whereas sero19A penicillin resistance (defined as a minimum inhibitor concentration [MIC] ≥2 μg/mL) increased significantly (from 28.7% to 43.7%). To better understand changes, we characterized sero19A isolates recovered during 2004-2008. METHODS: We performed antimicrobial susceptibility testing on all 2767 sero19A IPD isolates identified through the Centers for Disease Control Active Bacterial Core surveillance during 2004-2008. We genotyped 1804 (96.3%) of 1874 sero19A isolates recovered during 2005-2007 and all 148 year 2008 sero19A isolates from children <5 years of age. RESULTS: Resistant clonal complex (CC) 320/271(19A) increased from 20.9% (115 of 550) to 32.9% (208 of 633; P < .001) of IPD isolates during 2005-2007, which paralleled increased sero19A penicillin resistance (from 28.7% [163 of 567 isolates] to 39.5% [261 of 661 isolates]; P < .001). Total IPD due to 320/271(19A) increased during 2005-2007 and increased from 2.1 to 3.6 cases per 100,000 population during 2005-2008 in children <5 years of age. The penicillin-susceptible/intermediate, putative vaccine-escape CC695(19A) increased from 7.5% (41 of 550) to 13.6% (85 of 633) of sero19A isolates during 2005-2007 (P = .002). CONCLUSIONS:Sero19A rates may have plateaued; however, clonal shifts are increasing resistance. Increased IPD caused by CC320/271(19A) and CC695(19A) could reflect additional selective advantages in addition to resistance.
Authors: S S Richter; K P Heilmann; S L Coffman; H K Huynh; A B Brueggemann; M A Pfaller; G V Doern Journal: Clin Infect Dis Date: 2001-12-17 Impact factor: 9.079
Authors: L McGee; L McDougal; J Zhou; B G Spratt; F C Tenover; R George; R Hakenbeck; W Hryniewicz; J C Lefévre; A Tomasz; K P Klugman Journal: J Clin Microbiol Date: 2001-07 Impact factor: 5.948
Authors: R Sá-Leão; A Tomasz; I S Sanches; A Brito-Avô; S E Vilhelmsson; K G Kristinsson; H de Lencastre Journal: J Infect Dis Date: 2000-09-01 Impact factor: 5.226
Authors: Bernard Beall; M Catherine McEllistrem; Robert E Gertz; David J Boxrud; John M Besser; Lee H Harrison; James H Jorgensen; Cynthia G Whitney Journal: J Infect Dis Date: 2002-06-14 Impact factor: 5.226
Authors: C G Dowson; A Hutchison; J A Brannigan; R C George; D Hansman; J Liñares; A Tomasz; J M Smith; B G Spratt Journal: Proc Natl Acad Sci U S A Date: 1989-11 Impact factor: 11.205
Authors: S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards Journal: Pediatr Infect Dis J Date: 2000-03 Impact factor: 2.129
Authors: R Muñoz; T J Coffey; M Daniels; C G Dowson; G Laible; J Casal; R Hakenbeck; M Jacobs; J M Musser; B G Spratt Journal: J Infect Dis Date: 1991-08 Impact factor: 5.226
Authors: Robert E Gertz; M Catherine McEllistrem; David J Boxrud; Zhongya Li; Varja Sakota; Terry A Thompson; Richard R Facklam; John M Besser; Lee H Harrison; Cynthia G Whitney; Bernard Beall Journal: J Clin Microbiol Date: 2003-09 Impact factor: 5.948
Authors: Christian Massire; Robert E Gertz; Pavel Svoboda; Keith Levert; Matthew S Reed; Jan Pohl; Rachel Kreft; Feng Li; Neill White; Ray Ranken; Larry B Blyn; David J Ecker; Rangarajan Sampath; Bernard Beall Journal: J Clin Microbiol Date: 2012-03-21 Impact factor: 5.948
Authors: Grace M Lee; Ken Kleinman; Stephen I Pelton; William Hanage; Susan S Huang; Matthew Lakoma; Maya Dutta-Linn; Nicholas J Croucher; Abbie Stevenson; Jonathan A Finkelstein Journal: J Pediatric Infect Dis Soc Date: 2013-10-03 Impact factor: 3.164
Authors: Kristina G Hulten; Sheldon L Kaplan; Linda B Lamberth; William J Barson; José R Romero; Philana Ling Lin; John S Bradley; Laurence B Givner; Tina Q Tan; Jill A Hoffman; Edward O Mason Journal: J Clin Microbiol Date: 2013-02-06 Impact factor: 5.948
Authors: O Hurmic; N Grall; M Al Nakib; C Poyart; S Grondin; M-C Ploy; E Varon; J Raymond Journal: Eur J Clin Microbiol Infect Dis Date: 2014-06-15 Impact factor: 3.267